In this article

本文中

NVO

NVO

LLY

LLY

NVO

新愿景组织 (NVO)

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

Novo Nordisk

诺和诺德

stock fell over 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.

周一，该公司表示其下一代减肥药未能达到主要目标后，股票下跌超过10%。

The drug, CagriSema, didn't achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to

这种药物CagriSema在减重方面，与对照组相比，未能达到其主要终点，即证明其非劣效性。

Eli Lilly

礼来公司

's rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

诺和诺德在周一早上的一份声明中表示，其竞争对手的药物替西帕肽在84周后。

Eli Lilly

礼来公司

's stock rose 2.1% in premarket trading.

股票在盘前交易中上涨了2.1%。

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

诺和诺德表示，正在探索更多试验来测试CagriSema，包括更高剂量的组合。

This is breaking news. Please refresh for updates.

这是突发新闻。请刷新以获取更新。